Eli Lilly and Co

Innovent Biologics announces mazdutide clinical study results to be presented at EASD 60th Annual Meeting in Madrid, including Phase 3 DREAMS-2 study in type 2 diabetes. Mazdutide, a GLP-1R/GCGR dual agonist, shows superior blood sugar-lowering and weight loss efficacy. Innovent has two NDAs accepted by China's NMPA for review and five ongoing Phase 3 studies.

Tirzepatide, in Zepbound, reduced type 2 diabetes risk by 94% in obese or overweight adults with pre-diabetes, with sustained weight loss. Potential side effects include stomach and kidney issues, low blood sugar, and allergic reactions. Long-term effectiveness remains uncertain.

Deepak Bhatt, a prominent cardiologist, discussed common pitfalls in interpreting clinical trial data at the ESC Congress 2024. His work, cited over 275,000 times, focuses on pivotal trials like REDUCE-IT and SCORED. Bhatt highlighted the 17-year lag between scientific discovery and its adoption into clinical practice.

Eli Lilly announced retatrutide's trial results at ESC 2024, showing it reduced non-HDL-C, apoB, triglycerides, and improved lipid profiles in obese patients, potentially revolutionizing obesity treatment.

Multiple biotech companies raise significant funds for various medical advancements, including $600M for Symbiotic Capital targeting biotechnology, medical devices, diagnostics, and synthetic biology; $165M Series A for Third Arc Bio's multifunctional antibodies for oncology and autoimmunity; $144M Series B for Outpace Bio's AI-powered cell therapies for solid tumors; and others ranging from $126M for Halda Therapeutics' RIPTAC cancer therapies to $5M for Kano Therapeutics' targeted, non-viral DNA insertion technology.

Incretin-modulating therapies, including Wegovy and Zepbound, are transforming obesity treatment, impacting vital organs and offering a holistic approach to metabolic dysfunction-associated steatohepatitis (MASH). Despite early challenges, therapies like Novo Nordisk's semaglutide show promise in MASH Phase III trials. Dual agonism approaches, such as Zepbound and Boehringer Ingelheim's survodutide, demonstrate significant fibrosis improvement in Phase IIb results. Distinctions in receptor agonism effectiveness for MASH treatment are noted, with GLP-1/glucagon receptor agonists potentially more effective. Multiple companies, including Eli Lilly and Altimmune, are advancing their MASH therapies, with Phase III trials planned for 2024. The competitive MASH treatment pipeline emphasizes diverse mechanisms of action, with incretin-modulating treatments expected to be pivotal in future MASH management.

Lilly releases Zepbound (tirzepatide) single-dose vials, offering a 50% discount on list price of other incretin medicines for obesity, expanding access for adults with obesity, including those not eligible for savings card programs or without employer coverage.

Eli Lilly introduces single-dose vials of weight-loss drug Zepbound at half the price, available via LillyDirect, aiming to widen access and prevent unsafe copycat versions.

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, and resulted in sustained weight loss over a three-year treatment period.